Therapeutic Drug Monitoring of Vancomycin in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary Excretion Classification System (SECS)

Abstract

Vancomycin is a commonly used antibiotic for multi-drug resistant gram-positive infections treatment, especially methicillin-resistant Staphylococcus aureus (MRSA). Despite that, it has wide individual pharmacokinetic variability and nephrotoxic effect. Vancomycin trough concentrations for 57 Jordanian patients were measured in plasma and saliva through immunoassay and liquid chromatography-mass spectrometry (LC-MS/MS), respectively. Plasma levels were within accepted normal range, with exception of 6 patients who showed trough levels of more than 20 μg/ml and vancomycin was discontinued. Bayesian dose-optimizing software was used for patient-specific pharmacokinetics prediction and AUC/MIC calculation. Physiological-based pharmacokinetic (PBPK) vancomycin model was built and validated through GastroPlus™ 9.8 using in-house plasma data. A weak correlation coefficient of 0.2478 (P=0.1049) was found between plasma and saliva concentrations. The suggested normal saliva trough range of vancomycin is 0.01906 to 0.028589 (μg/ml). Analysis of variance showed significant statistical effects of creatinine clearance and albumin concentration on dose-normalized Cmin plasma and saliva levels respectively, which is in agreement with PBPKmodeling. It can be concluded that saliva is not a suitable matrix for TDM of vancomycin. Trough levels in plasma matrix should always be monitored for the safety of patients.

Key words

TDM - Vancomycin - Pharmacokinetics - SECS - PBPK - GastroPlus

Publikationsverlauf

Eingereicht: 09. März 2022

Angenommen: 09. Mai 2022

Artikel online veröffentlicht:
27. Juni 2022

• References

• 1 Levine DP. Vancomycin: A history. Clinical Infectious Diseases, 42(Supplement_1) 2006;
• 2 Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Science 2020; 29: 654-669
• 3 Huang V, Clayton NA, Welker KH. Glycopeptide hypersensitivity and adverse reactions. Pharmacy 2020; 8: 70
• 4 Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clinical Pharmacology & Therapeutics 2017; 102: 459-469
• 5 Lade H, Kim J-S. Bacterial targets of antibiotics in methicillin-resistant Staphylococcus aureus. Antibiotics 2021; 10: 398
• 6 Wilson JW, Estes LL. Vancomycin adult dosing and monitoring. Oxford Medicine Online 2012;
• 7 Larry AB. Vancomycin. In Applied Clinical Pharmacokinetics, 3rd edition 2014; pp. 315-452 essay, McGraw-Hill Education / Medical
• 8 Cunha BA. Vancomycin. Medical Clinics of North America 1995; 79: 817-831
• 9 Cusumano JA, Klinker KP, Huttner A. et al. Towards precision medicine: Therapeutic drug monitoring–guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity. American Journal of Health-System Pharmacy 2020; 77: 1104-1112
• 10 Idkaidek N, Hamadi S, Bani-Domi R. et al. Saliva versus plasma therapeutic drug monitoring of gentamicin in Jordanian preterm infants. development of a physiologically-based pharmacokinetic (PBPK) model and validation of class II drugs of salivary excretion classification system. Drug Research 2020; 70: 455-462
• 11 Idkaidek N, Arafat T. Saliva versus plasma pharmacokinetics: Theory and application of a salivary excretion classification system. Molecular Pharmaceutics 2012; 9: 2358-2363
• 12 Sager JE, Yu J, Ragueneau-Majlessi I. et al. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: A systematic review of published models, applications, and model verification. Drug Metabolism and Disposition 2015; 43: 1823-1837
• 13 Jones HM, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: Pharmacometrics& Systems Pharmacology 2013; 2: 63
• 14 Zhang F, Bartels M, Clark A. et al. Performance evaluation of the GASTROPLUSTM software tool for prediction of the toxicokinetic parameters of chemicals. SAR and QSAR in Environmental Research 2018; 29: 875-893
• 15 Ferreira A, Martins H, Oliveira JC. et al. PBPK modeling and simulation of antibiotics amikacin, gentamicin, tobramycin, and vancomycin used in hospital practice. Life 2021; 11: 1130
• 16 Mali NB, Deshpande SP, Wandalkar PP. et al. Single-dose and Steady-statePharmacokinetics of Vancomycin in Critically Ill Patients Admitted to MedicalIntensive Care Unit of India. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2019; 23: 513-517
• 17 GastroPlus^® manual, Simulation Plus, California, USA
• 18 Emoto C, Johnson TN, McPhail BT. et al. Using a vancomycin PBPK model in special populations to elucidate case-based clinical PK observations. . CPT: Pharmacometrics& Systems Pharmacology 2018; 7: 237-250